Silver Bullet Therapeutics was allowed a U.S. patent, “Bone Implants for the Treatment of Infection.” Further, the company has entered an expedited CE Mark filing for a significantly expanded OrthoFuzIon Antimicrobial Bone Screw.
During 2015, Silver Bullet announced four new U.S. patents relating to its technology that employs antimicrobial metal ions to prevent infection. According to The American College of Surgeons National Surgical Quality Improvement Program, surgical site infections (SSIs) represent 18.5% of the top reasons for hospital readmission following total hip or total knee arthroplasty.
While not orthopaedic-specific, the company cites statistics that support the need for antimicrobial medical devices in general: healthcare-associated infections (HAIs) caused from antimicrobial growth on medical devices is estimated to cost the U.S. healthcare system >US $35BB annually, with CDC figures suggesting that SSIs comprise >30% of all HAIs in hospitalized patients.
Silver Bullet Therapeutics was allowed a U.S. patent, "Bone Implants for the Treatment of Infection." Further, the company has entered an expedited CE Mark filing for a significantly expanded OrthoFuzIon Antimicrobial Bone Screw.
During 2015, Silver Bullet announced four new U.S....
Silver Bullet Therapeutics was allowed a U.S. patent, “Bone Implants for the Treatment of Infection.” Further, the company has entered an expedited CE Mark filing for a significantly expanded OrthoFuzIon Antimicrobial Bone Screw.
During 2015, Silver Bullet announced four new U.S. patents relating to its technology that employs antimicrobial metal ions to prevent infection. According to The American College of Surgeons National Surgical Quality Improvement Program, surgical site infections (SSIs) represent 18.5% of the top reasons for hospital readmission following total hip or total knee arthroplasty.
While not orthopaedic-specific, the company cites statistics that support the need for antimicrobial medical devices in general: healthcare-associated infections (HAIs) caused from antimicrobial growth on medical devices is estimated to cost the U.S. healthcare system >US $35BB annually, with CDC figures suggesting that SSIs comprise >30% of all HAIs in hospitalized patients.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
